Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
These modules will act as a guide to doctors and health care workers to deal with post-Covid-19 issues
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
Coordinated and collaborative efforts will strongly contribute to the achievement of shared goals faster: Mandaviya
The facility has the capacity to produce one crore doses per day
The clinical research organisation located in Hyderabad is a USFDA inspected facility
It is the first branded generic alternative to Fostair 100/6 pMDI
The government plans to enrol over 50 crore people and empanel more hospitals under the scheme. The scheme provides a cover of Rs 5 lakh per family per year
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Subscribe To Our Newsletter & Stay Updated
